A Dinucleotide Deletion in the CD24 Gene Is a Potential Risk Factor for Colorectal Cancer

Abstract

Background

CD24 is a sialoglycoprotein anchored to the cell surface via glycosylphosphatidylinositol and is involved in intracellular signaling processes. It plays an important role in the early stages of the multistep process of colorectal carcinogenesis. Several single nucleotide polymorphisms in the CD24 gene are reported to exert a diverse effect on cancer risk. We aimed to elucidate whether CD24 TG/del genetic variants are associated with susceptibility to colorectal cancer (CRC).

Methods

The study included 179 subjects, 36 with CRC (prior to surgery) and 143 healthy control subjects. Deoxyribonucleic acid was purified from peripheral blood leukocytes, and by using restriction fragment length polymorphism analysis, the CD24 gene was genotyped for the specific genetic variant, TG deletion. Additionally, CD24 protein expression levels were determined by Western blotting analysis.

Results

The incidence of the TG/del was higher among the CRC patients compared with healthy controls, 14% and 10%, respectively (P = .54). CD24 protein levels were significantly higher among CRC patients. There were no significant differences in CD24 expression between CRC patients at different stages of the disease or between patients who carry the mutation and those who did not.

Conclusions

CD24 genetic variant might be of clinical value for risk assessment as part of cancer prevention programs. Further study on larger populations is needed to validate the importance of this dinucleotide deletion in CRC development. Overexpression of CD24 protein occurs early along the multistep process of CRC carcinogenesis, and a simple blood sample based on CD24 expression on peripheral blood leukocytes can contribute to early diagnosis.

Keywords

colorectal cancer CD24 polymorphism

Get full access to this article

View all access options for this article.

References

Bray

Ferlay

Soerjomataram

Siegel

RL.

Torre

LA.

Jemal

. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.doi:10.3322/caac.21492

http://www.ncbi.nlm.nih.gov/pubmed/30207593

Colorectal (Colon) Cancer Centers for Disease Control and Prevention [cited 2015]. 2015. http://www.cdc.gov/cancer/ colorectal/

International Agency for Research on Cancer. 2018. http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf

International Agency for Research on Cancer. 2018. http://gco.iarc.fr/today/data/factsheets/populations/376-israel-fact-sheets.pdf

Fearon

ER.

Vogelstein

. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.doi:10.1016/0092-8674(90)90186-I

http://www.ncbi.nlm.nih.gov/pubmed/2188735

Vogelstein

Fearon

ER.

Hamilton

et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-532.doi:10.1056/NEJM198809013190901

http://www.ncbi.nlm.nih.gov/pubmed/2841597

Bos

JL.

Fearon

ER.

Hamilton

et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293-297.doi:10.1038/327293a0

http://www.ncbi.nlm.nih.gov/pubmed/3587348

Bos

. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.http://www.ncbi.nlm.nih.gov/pubmed/2547513

Sagiv

Memeo

Karin

et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006;131(2):630-639.doi:10.1053/j.gastro.2006.04.028

http://www.ncbi.nlm.nih.gov/pubmed/16890615

10.

Baumann

Cremers

Kroese

et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005;65(23):10783-10793.doi:10.1158/0008-5472.CAN-05-0619

http://www.ncbi.nlm.nih.gov/pubmed/16322224

11.

Ayre

DC.

Christian

. Cd24: a rheostat that modulates cell surface receptor signaling of diverse receptors. Front Cell Dev Biol. 2016;4:146.doi:10.3389/fcell.2016.00146

http://www.ncbi.nlm.nih.gov/pubmed/28083532

12.

Kristiansen

Sammar

Altevogt

. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004;35(3):255-262.doi:10.1023/B:HIJO.0000032357.16261.c5

http://www.ncbi.nlm.nih.gov/pubmed/15339045

13.

Naumov

Zilberberg

Shapira

et al. CD24 knockout prevents colorectal cancer in chemically induced colon carcinogenesis and in APC(Min)/CD24 double knockout transgenic mice. Int J Cancer. 2014;135(5):1048-1059.doi:10.1002/ijc.28762

http://www.ncbi.nlm.nih.gov/pubmed/24500912

14.

Sagiv

Starr

Rozovski

et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008;68(8):2803-2812.doi:10.1158/0008-5472.CAN-07-6463

http://www.ncbi.nlm.nih.gov/pubmed/18413748

15.

Zhou

Rammohan

Lin

et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100(25):15041-15046.doi:10.1073/pnas.2533866100

http://www.ncbi.nlm.nih.gov/pubmed/14657362

16.

Wang

Liu

et al. A hypermorphic SP1 binding CD24 variant associates with risk and progression of multiple sclerosis. Am J Transl Res. 2012;4(3):347-356.http://www.ncbi.nlm.nih.gov/pubmed/22937211

17.

Wang

Lin

Rammohan

et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet. 2007;3(4):e49.doi:10.1371/journal.pgen.0030049

http://www.ncbi.nlm.nih.gov/pubmed/17411341

18.

Huang

X-L.

D-H.

Wang

G-P.

Zhang

C-G

. Associations between CD24 gene polymorphisms and inflammatory bowel disease: a meta-analysis. World J Gastroenterol. 2015;21(19):6052-6059.doi:10.3748/wjg.v21.i19.6052

http://www.ncbi.nlm.nih.gov/pubmed/26019472

19.

Lisiansky

Kraus

Naumov

et al. Role of CD24 polymorphisms in the susceptibility to inflammatory bowel disease. Int J Biol Markers. 2014;29(1):e62-e68.doi:10.5301/jbm.5000072

http://www.ncbi.nlm.nih.gov/pubmed/24557789

20.

Diaz-Gallo

L-M.

Medrano

LM.

Gómez-García

et al. Analysis of the influence of two CD24 genetic variants in Crohn’s disease and ulcerative colitis. Hum Immunol. 2011;72(10):969-972.doi:10.1016/j.humimm.2011.05.028

http://www.ncbi.nlm.nih.gov/pubmed/21684315

21.

Miller

SA.

Dykes

DD.

Polesky

. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.doi:10.1093/nar/16.3.1215

http://www.ncbi.nlm.nih.gov/pubmed/3344216

22.

Lee

J-H.

Kim

S-H.

Lee

E-S.

Kim

Y-S

. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep. 2009;22(5):1149-1156.doi:10.3892/or_00000548

http://www.ncbi.nlm.nih.gov/pubmed/19787233

23.

Lee

HJ.

Choe

Jheon

Sung

S-W.

Lee

C-T.

Chung

J-H

. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol. 2010;5(5):649-657.doi:10.1097/JTO.0b013e3181d5e554

http://www.ncbi.nlm.nih.gov/pubmed/20354454

24.

Kraus

Shapira

Kazanov

et al. Predictive levels of CD24 in peripheral blood leukocytes for the early detection of colorectal adenomas and adenocarcinomas. Dis Markers. 2015;2015:1-9.doi:10.1155/2015/916098

http://www.ncbi.nlm.nih.gov/pubmed/26078485

25.

Jacob

Bellach

Grützmann

et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology. 2004;4(5):454-460.doi:10.1159/000079824

http://www.ncbi.nlm.nih.gov/pubmed/15256807

26.

Senner

Sturm

Baur

Schrell

UH.

Distel

Paulus

. Cd24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol. 1999;58(8):795-802.doi:10.1097/00005072-199908000-00002

http://www.ncbi.nlm.nih.gov/pubmed/10446804

27.

Aigner

Ramos

CL.

Hafezi-Moghadam

et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. Faseb J. 1998;12(12):1241-1251.doi:10.1096/fasebj.12.12.1241

http://www.ncbi.nlm.nih.gov/pubmed/9737727

28.

Lim

. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother. 2005;59(suppl 2):S351-S354.doi:10.1016/S0753-3322(05)80076-9

http://www.ncbi.nlm.nih.gov/pubmed/16507407

29.

Marmé

Werft

Walter

et al. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res Treat. 2012;132(3):819-831.doi:10.1007/s10549-011-1759-9

http://www.ncbi.nlm.nih.gov/pubmed/21960110

30.

Shamai

Nabiochtchikov

Kraus

et al. CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. PLoS One. 2015;10(9):e0134469.doi:10.1371/journal.pone.0134469

http://www.ncbi.nlm.nih.gov/pubmed/26394139